menu
    • menu
    [{"orgOrder":0,"company":"Rafael Holdings","sponsor":"Cyclo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Rafael Holdings","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Rafael Holdings \/ Rafael Holdings","highestDevelopmentStatusID":"10","companyTruncated":"Rafael Holdings \/ Rafael Holdings"},{"orgOrder":0,"company":"Rafael Holdings","sponsor":"Cyclo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Rafael Holdings","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Rafael Holdings \/ Rafael Holdings","highestDevelopmentStatusID":"10","companyTruncated":"Rafael Holdings \/ Rafael Holdings"},{"orgOrder":0,"company":"Rafael Holdings","sponsor":"Cyclo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Rafael Holdings","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rafael Holdings \/ Cyclo Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Rafael Holdings \/ Cyclo Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Rafael Holdings

    Menu

    Rafael Holdings

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Rafael Holdings

                            U.S.A arrow
                            Biotech Week Boston
                            Not Confirmed

                            Rafael Holdings

                            U.S.A arrow
                            Biotech Week Boston
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Sponsor : Cyclo Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

                            Details : The combined company will focus on the development of Trappsol Cyclo (hydroxypropyl-beta cyclodextrin) for the treatment of Niemann-Pick Disease Type C1.

                            Product Name : Trappsol Cyclo

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            August 22, 2024

                            Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Sponsor : Cyclo Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Rafael Holdings

                            U.S.A arrow
                            Cell Therapy
                            Not Confirmed

                            Rafael Holdings

                            U.S.A arrow
                            Cell Therapy
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Recipient : Cyclo Therapeutics

                            Deal Size : $5.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 M...

                            Details : Cyclo Therapeutics intends to use the proceeds for the support of its Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug designated product in the United States and Europe, under clinical trial for Niemann-Pick Disease Type C, a rare and fa...

                            Product Name : Trappsol Cyclo

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 06, 2023

                            Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Recipient : Cyclo Therapeutics

                            Deal Size : $5.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Rafael Holdings

                            U.S.A arrow
                            Biotech Week Boston
                            Not Confirmed

                            Rafael Holdings

                            U.S.A arrow
                            Biotech Week Boston
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Recipient : Cyclo Therapeutics

                            Deal Size : $5.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.

                            Details : Cyclo Therapeutics intends to use the proceeds to support of its Trappsol Cyclo, a proprietary formulation of hydroxypropyl beta cyclodextrin being developed in clinical trials for the potential treatment of Niemann-Pick Disease Type C1, a rare, fatal an...

                            Product Name : Trappsol Cyclo

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            February 08, 2023

                            Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Recipient : Cyclo Therapeutics

                            Deal Size : $5.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth